In June, selected into the fourth batch of "3551 Optical Valley Talent Program" (Dr. Zhou Pengfei).

In July, officiallyestablished in Biolake,national biologicalindustry base in Wuhan.

In November, won the honor of "Top TenEnterprises with Outstanding Contribution" in Wuhan National BiologicalIndustrial Base.

In April, Academician Honghao Zhou was introduced to establish YZY Personalized Medicine Research Center.
In August, built 1200 square meters of standard production workshop conforming to ISO13485.
In November, obtained Medical Device Production Licence.
In December, obtained Permits for Medical Device Operation.

In April, successfully passed the assessment of quality management system of in vitro diagnostic reagent manufacturer.
In May, won the "Best Management Enterprise Award" on the third anniversary of the construction of Wuhan National Biological Industrial Base.
In June, selected into the sixth batch of "3551 Optical Valley Talent Program" (Dr. Cai Congli).

In January, KRAS and EGFR Gene Mutation Detection Kit obtained Class III medical device registration certificate by NMPA.
In December, established Wuhan Textile University and YZY Joint Research Center for Micro-Nano Mecine.

In March, CYP2C19 Gene Mutation Detection Kit and other 3 products obtained Class Ⅲ Medical Device Registration Certificate by NMPA.
In March, Autoanalyzer system on abnormal cell obtained Class Ⅱ Medical Device Registration Certificate.
In July, awarded the title of "Key Overseas Chinese Entrepreneurial Team" by Overseas Chinese Affairs Office of the State Council .
In October, obtained A round financing of 24 million yuan from Elite Capital.
In November, won the third prize in the "Yellow Crane Cup" High-level Talent Entrepreneurship Project Competition.

In April, awarded Contractor of Gene Detection Demonstration Center by National Development and Reform Commission.
In July, selected into the third batch of Intellectual Property Demonstration Construction Enterprises in Hubei Province.
In July,  officially listed on New OTC Market.
In August, ALK and other 3 products obtained the Class III Medical Device Registration Certificate by NMPA.
In September, selected into the ninth batch of "3551 Optical Valley Talent Program" (Dr. Kan Liu).
In December, obtained A+ round financing of 65 million yuan from Beilu Pharmaceutical.
In December, selected as the first batch of supported enterprises for "1,000 Great Enterprises and 10, 000 innovative Talents" Program in Wuhan.

In March, moved into the new office building of 4,000 square meters.
In July, ALDH2 and other two products obtained Class III Medical Device Registration Certificate by NMPA.
In November, awarded "Enterprise Research and Development Center" in Wuhan.
In December, passed the certification from National Intellectual Property Management System .

In June, listed as Industrial Enterprises above National Scale.
In September, accredited as New "Little Giant" Technology Enterprise in Wuhan.
In November, selected as Top 20 Fast Growing High-tech companies in Optics Valley in 2018.
In November, passed the reassessment of National High-Tech Enterprise.

In October,  selected as "Golden Seed"  back-up stock listing enterprise in Wuhan in 2019.
In October, obtained Class II Medical Device Registration Certificate for Slide Scanning Image System（YZY- CTC-D800).
In November, selected as the third batch of Invisible Champion Cultivation Enterprises in the Subdivision Field of Pillar Industries in Hubei Province.

In May, selected as "Golden Seed" back-up stock listing enterprise in Hubei Province from Year 2020 to 2021.
In September, selected as the “Gold Seed” Stock listed Enterprise in East Lake High-tech Development Zone in 2020.
In September, won the first prize of Hubei Science and Technology Progress Award in 2020.
In September, passed the Management System Certification on the Integration of Informatization and Industrialization.
In November, built over 2,200 square meters of new production workshops conforming to ISO13485 standards.
In December,  obtained B-round financing of 50 million Yuan from Haitong-Fortis fund and Tongji Modern Medical Fund.

In January, wholly acquired Bioda Diagnostics (Wuhan) Co., LTD.
In March, awarded the second prize of 2020 China Medical Science and Technology Award.
In April, the subsidiary, Youxingtong Co. obtained the Permits for Medical Device Operation.
In June, selected into the TOP 50 Glory List in Wuhan in 2021.
In October, selected as 2021 "Gazelle Enterprise" in East Lake High-tech Development Zone.
In October, selected as the first batch of "New Species" Enterprises (Gazelle Enterprises) on Technological Innovation in Hubei Province.
In November,  selected as Golden Seed" back-up stock listing enterprise in Wuhan in 2021.
In November, selected as the "Golden Seed" enterprise in Wuhan East Lake High-tech Development Zone in 2021.
In November, passed the reassessment of National High and New Technology Enterprise.
In December, selected as Specialize and New "Little Giant" Enterprise in Hubei Province.

In March, the hypertension gene detection kit obtained the NMPA Class III Medical Device

Registration Certificate.

In August, the company was selected as the Hubei Province Enterprise Technology Center.

In September, the company was selected as 2022 National Intellectual Property Advantage

Enterprise.

In October, Human Leukocyte B site 5801 gene detection kit obtained the NMPA Class III

MedicalDevice Registration Certificate.

In March, the hypertension gene detection kit was selected as an outstanding 

high-tech product by the Wuhan High-tech Industry Association.

In May, Dr. Wei Liang and Dr. Guo Jing were selected as innovative talents and 

outstanding young talents of the "3551 Optics Valley Talent Plan".

In November, the CTC detection system was selected for the "Hubei Province 

Innovation Product Application Demonstration Recommended Catalog (2023 Edition)".

In December, the HER2 gene detection kit obtained the NMPA Class III Medical Device 

Registration Certificate .